AQST — Aquestive Therapeutics, Inc. Stock Price, Chart & AI Report

Negative May 2, 2026 • 20:00 UTC GlobeNewswire Inc. • Rosen Law Firm

AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.

AQST securities class action lead plaintiff deadline New Drug Application Anaphylm sublingual film false statements investor damages

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements regarding its NDA for Anaphylm, specifically concealing critical human factors issues with its product. This indicates potential regulatory problems, product safety concerns, and investor losses.

Negative Apr 30, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.

ATRA SLNO AQST class action lawsuit securities fraud Atara Biotherapeutics tabelecleucel FDA approval

Sentiment note

A class action lawsuit has been filed against this company for alleged securities fraud violations, indicating similar investor harm concerns.

Negative Apr 30, 2026 • 00:04 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role

A class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquestive's stock price plummeted 37% from $6.21 to $3.91 per share. Investors who purchased shares between June 16, 2025 and January 8, 2026 have until May 4, 2026 to apply as lead plaintiff.

AQST class action lawsuit FDA deficiencies NDA approval Anaphylm PDUFA date stock price decline securities fraud

Sentiment note

The company is accused of creating false impressions about FDA approval prospects for Anaphylm, concealing known deficiencies. The resulting 37% stock price drop and class action lawsuit indicate significant investor harm and loss of confidence in company management's transparency and credibility.

Negative Apr 28, 2026 • 13:00 UTC GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.

AQST class action lawsuit securities fraud FDA approval NDA deficiencies stock price decline Anaphylm drug PDUFA date

Sentiment note

The company is the subject of a class action lawsuit alleging false and misleading statements regarding FDA drug approval prospects. The stock experienced a significant 37% price decline following disclosure of FDA deficiencies, indicating investor loss and loss of confidence in company management's credibility.

Negative Apr 27, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements about the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.

AQST class action lawsuit securities fraud Aquestive Therapeutics FDA approval Anaphylm NDA investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements about drug approval timelines and concealment of significant regulatory risks. This represents serious allegations of investor deception and potential financial harm.

Negative Apr 26, 2026 • 02:29 UTC GlobeNewswire Inc. • Rosen Law Firm

AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm is encouraging investors who suffered losses in securities class action lawsuits against Aquestive Therapeutics, Babcock & Wilcox Enterprises, and Snowflake Inc. to secure legal counsel before upcoming deadlines. The firm is seeking lead plaintiffs for cases involving alleged false statements and disclosure failures.

AQST BW BWNB BWPA securities class action investor losses lead plaintiff deadline false statements

Sentiment note

Company is subject to securities class action lawsuit alleging false/misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues with sublingual film packaging and administration.

Negative Apr 23, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.

AQST class action lawsuit securities fraud Aquestive Therapeutics FDA approval Anaphylm NDA investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misstatements about drug approval timelines and concealment of regulatory risks, which indicates serious corporate governance and disclosure violations that harmed investors.

Negative Apr 21, 2026 • 19:59 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSE

Pomerantz Law Firm has filed class action lawsuits against Eos Energy Enterprises, Nektar Therapeutics, and Aquestive Therapeutics for alleged securities fraud. Eos Energy's stock fell 39.44% after missing earnings estimates significantly, with the company citing production issues and quality control problems.

EOSE NKTR AQST class action lawsuit securities fraud Eos Energy Enterprises Nektar Therapeutics Aquestive Therapeutics

Sentiment note

Class action lawsuit filed against the company for alleged securities fraud or unlawful business practices.

Negative Apr 21, 2026 • 19:59 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

Pomerantz Law Firm has filed class action lawsuits against Aquestive Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics, alleging securities fraud and unlawful business practices. The lawsuit against Aquestive was triggered by an FDA letter identifying deficiencies in the Anaphylm NDA review, causing the stock to drop 37% on January 9, 2026. Investors have until May 4, 2026, to request Lead Plaintiff status.

AQST EOSE NKTR class action lawsuit securities fraud FDA deficiency letter stock price decline Lead Plaintiff deadline

Sentiment note

Company faces class action lawsuit for alleged securities fraud; FDA identified deficiencies in Anaphylm NDA precluding labeling discussions, resulting in indefinite approval delay and 37% stock price drop on January 9, 2026.

Negative Apr 19, 2026 • 17:07 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

Rosen Law Firm is reminding investors who purchased Aquestive Therapeutics securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.

AQST securities class action lead plaintiff deadline New Drug Application Anaphylm sublingual film false statements investor damages

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements regarding its NDA for Anaphylm, with specific claims that Aquestive concealed or minimized significant human factors issues in product design and labeling, resulting in investor damages.

Negative Apr 17, 2026 • 13:00 UTC GlobeNewswire Inc. • The Gross Law Firm

AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

Aquestive Therapeutics faces a securities class action lawsuit covering the period June 16, 2025 to January 8, 2026. The company allegedly made false statements about its Anaphylm drug application while concealing material facts about human factors in the sublingual film's use. On January 9, 2026, the FDA identified deficiencies that delayed approval, causing the stock to plummet 37% in a single day from $6.21 to $3.91 per share.

AQST securities class action Aquestive Therapeutics FDA deficiencies Anaphylm misleading statements stock decline New Drug Application

Sentiment note

The company is facing a securities class action lawsuit for allegedly providing false and misleading statements about its drug application while concealing material facts. The FDA identified deficiencies that delayed approval, resulting in a dramatic 37% single-day stock price decline, indicating significant investor losses and regulatory setbacks.

Negative Apr 16, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aquestive Therapeutics and certain officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of Anaphylm and concealed significant human factors risks associated with the sublingual film product that could impact regulatory approval.

AQST GOSS SLNO class action lawsuit securities fraud FDA approval NDA Anaphylm

Sentiment note

Company faces securities fraud allegations for making false statements about drug approval timelines and concealing material risks related to product development. The lawsuit indicates potential investor losses and regulatory setbacks for the Anaphylm NDA.